{
    "code": "02025303",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02025303",
    "time": "2020-10-30 03:56:55",
    "許可證字號": "衛署藥輸字第025303號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "114\/12\/03",
    "發證日期": "99\/12\/03",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA00202530309",
    "中文品名": "總動原注射劑",
    "英文品名": "Mozobil solution for injection",
    "適應症": "成人\r\n與顆粒球群落形成刺激因子(G-CSF)併用，驅動造血幹細胞至周邊血液供收集以施行自體移植；適用於須施行自體移植之非何杰金氏淋巴瘤或多發性骨髓瘤的成人病人，但驅動不佳者。\r\n\r\n兒童 (1歲至小於18歲)\r\n與顆粒球群落形成刺激因子(G-CSF)併用，驅動造血幹細胞至周邊血液供收集以施行自體移植；適用於患有淋巴瘤或實體惡性腫瘤及有以下任一情況的兒童：\r\n-使用G-CSF驅動後，循環中的造血幹細胞在預期收集當天所能收集到的細胞數太少(不論是否併用化療)，或\r\n-先前曾無法收集到足量的造血幹細胞。",
    "劑型": "270注射劑",
    "包裝": "100支以下盒裝 24毫克\/1.2毫升\/小瓶小瓶裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "",
    "主成分略述": "PLERIXAFOR",
    "限制項目": "02輸　入 58依本署891212衛署藥字第0890035812號公告經本署認定得免除國內銜接性試驗且經本署核定之新藥",
    "申請商名稱": "1424601100  賽諾菲股份有限公司",
    "申請商地址": "台北市信義區松仁路3號7樓",
    "主製造廠": [
        {
            "製造廠名稱": "MUS1010000  GENZYME CORPORATION",
            "製造廠廠址": "1125 PLEASANTVIEW TERRACE RIDGEFIELD, NJ 07657, U.S.A.",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": ""
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "FGB0200000  GENZYME LIMITED",
            "製造廠廠址": "37 HOLLANDS ROAD, HAVERHILL, SUFFOLK, CB9 8PU, UNITED KINGDOM",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED KINGDOM",
            "製程": "包裝"
        },
        {
            "製造廠名稱": "FUS0348100  GENZYME CORPORATION",
            "製造廠廠址": "500 KENDALL STREET, CAMBRIDGE, MA 02142, U.S.A.",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": "總公司"
        }
    ],
    "CCC號列": "30049071005 抗癌藥Anti-cancer preparations",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "9200092800",
            "成分名稱": "PLERIXAFOR",
            "含量描述": "",
            "含量": "20.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "109.9.3_Mozobil_LPI_C_CCDS v9 + PI validation_HA final comment_2020.09.03 annotated-109-09-11.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025303&Seq=009&Type=9"
        },
        {
            "title": "內袋標籤_202006-109-07-16.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025303&Seq=007&Type=8"
        },
        {
            "title": "外盒標籤_202006-109-07-16.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025303&Seq=006&Type=8"
        }
    ]
}